p e r s p e c t i v e
Mesenchymal stem cells (MSCs) are the focus of intensive efforts worldwide directed not only at elucidating their nature and unique properties but also developing cell-based therapies for a diverse range of diseases. More than three decades have passed since the original formulation of the concept, revolutionary at the time, that multiple connective tissues could emanate from a common progenitor or stem cell retained in the postnatal bone marrow. Despite the many important advances made since that time, substantial ambiguities still plague the field regarding the nature, identity, function, mode of isolation and experimental handling of MSCs. These uncertainties have a major impact on their envisioned therapeutic use.
Narrowing the focus on the stem cell Unbeknown to most readers of the copious literature dealing with both fundamental and clinical aspects of MSC biology, the current, widespread general concept of MSCs represents the modification (incorrect, we will argue herein) of a notion that is both classical and solidly proven experimentally. This notion is that postnatal human (or, more generally, mammalian) bone marrow includes a subset of nonhematopoietic, stromal cells that are both multipotent and selfrenewing. Although the multipotency of bone marrow-derived MSCs has long been recognized (summarized in Owen and Friedenstein 1 ), the ability of MSCs to self-renew has only recently been supported by the proper in vivo evidence (Box 1) 2, 3 . When transplanted in vivo, these cells generate a miniature bone organ with proper histology and architecture in which hematopoiesis from the recipient animal becomes established. These cells are, or can be usefully conceptualized as, bona fide stem cells for all tissues that are found within a skeletal segment (that is, a single bone): bone tissue itself, cartilage, adipocytes, fibroblasts and hematopoiesis-supporting stroma.
All of these tissues are generated in vivo in proper transplantation assays, and all are generated from a single cell, if a single cell is originally isolated and used to generate a transplantable clonal progeny (reviewed in Bianco et al. 4 ). This concept is rooted in a line of experimentation originating in the 1960s. Progressively refined since then, in vivo transplantation experiments have stepwise assigned the originally observed skeletogenic potential of bone marrow: it was first assigned to uncultured bone marrow tissue as a whole, 5 then to its nonhematopoietic (stromal) cells, then to a subset of stromal cells capable of initiating clonal growth ex vivo (colony-forming unit fibroblasts (CFU-Fs)) 6 and, ultimately, to an in vivo-identified perivascular (adventitial) cell that is amenable to prospective isolation on the basis of phenotype ( Fig. 1) 2, 3 .
What's in a name
Whether called a mesenchymal stem cell, as proposed by Caplan 7 and Pittenger et al. 8 , or, more stringently (on the basis of its proven in vivo differentiation potential), a skeletal stem cell 9 , this cell is a precisely defined physical and conceptual entity.
Physically, this cell resides at the outer surface of sinusoids, a characteristic type of blood vessel in the bone marrow, in a subendothelial (mural) position (Fig. 1) . It is part of a three-dimensional perivascular stromal compartment in the bone marrow that originates during the organogenesis of bone from committed osteogenic cells that reside at the primitive perichondrium and invade the bone anlage along with growing blood vessels ( Fig. 2) 4, [10] [11] [12] [13] [14] . A range of surface markers allows for prospective isolation of perisinusoidal MSCs (CD146, CD105, alkaline phosphatase (ALP) and STRO-1) and vascular cell adhesion molecule 1 (VCAM1) in humans 2 and CD105, CD90 and VCAM1 in mouse (pending further refinement)) 15 . Some of these proteins can also be used as in situ markers in intact bone marrow or heterotopic transplants. The transcriptome of bone marrow MSCs combines the expression of genes characteristic of committed early osteogenic cells (including the osteogenic master gene, Runx2) with that of genes characteristic of perivascular cells 2 .
Conceptually, an MSC is a single cell that is capable of generating a complete heterotopic bone or bone marrow organ (ossicle) in vivo, including a compartment of perivascular stromal cells with similar phenotypes and properties as the originally explanted cell 2 . This in vivo potential is system restricted and cell autonomous, meaning it excludes the potential to generate nonskeletal tissues and does not require cueing with factors to induce a skeletogenic transcriptional program, namely bone morphogenic proteins (BMPs). Importantly, the self-renewing progenitor of skeletal tissues is the organizer of both the hematopoietic microenvironment and the hematopoietic p e r s p e c t i v e niche in bone marrow 2, 3, 16 . Both arms of this dual function are of paramount physiological importance; only one arm (the capacity to generate structural tissue components of bone) has been the focus of translational attempts to date. Implications of the other arm, however, are substantial: the niche function of bone marrow MSCs, by itself, has the potential to lead to strategies for harnessing the regulation of hematopoietic stem cells (HSCs) or modeling and targeting the interaction of hematopoietic and nonhematopoietic cancer with the bone environment.
"As we may think" 17 As in other fields of stem-cell biology, which underpin or complement successful clinical application, the fundamental tenets of stem-cell biology (in vivo transplantation and analysis at the single-cell level) allowed for the identification of a bona fide stem cell for skeletal tissues and provided direct in vivo evidence for its translational potential. The progenitors of skeletal tissues that have been directly proven to generate bone and other skeletal tissues in transplantation models were logically envisioned as fundamental tools for the regeneration of bone in a number of clinical scenarios: first and foremost, the repair of localized bone defects through local transplantation of either cells or cell-material constructs that would restore bone integrity after trauma or extirpative surgery 18 .
In any organ system, however, the very notion of stem cells as fundamental postnatal units of organ or tissue regeneration modifies our understanding of organ physiology and the way in which individual diseases can be thought of or modeled mechanistically. It also encourages, per se, visions of therapy even more daring than tissue engineering. For example, we now know that certain genetic skeletal diseases are best investigated, modeled in vivo 19 or even genetically corrected in vitro in skeletal stem cells 20 . Our ability to identify and handle hematopoietic or epithelial progenitor and stem cells has enabled the correction of lethal genetic diseases through gene therapy in stem cells, including adenosine deaminase severe Box 1 What defines a (mesenchymal) stem cell: transplantation assays All definitions of stem cells are functional in nature, and all types of stem cells are defined by functional assays. These definitions aim to prove the capacity of the stem cells to generate fully differentiated tissues in vivo-multipotency-and their ability to reconstitute in vivo cells identical in phenotype and potency to those explanted-self renewal. For each type of stem cell, all these in vivo assays are simply the legacy of the seminal experiments that first revealed their defining functional properties. For example, functional identification of pluripotent (embryonic or reprogrammed) stem cells requires teratoma formation, generation of chimeras and germline transmission. Functional identification of hematopoietic stem cells requires long-term hematopoietic reconstitution through serial transplantation. The identification of defining functional properties through in vivo experiments precedes, and is indispensable for, the identification of molecular markers of stem cells. Specifically intended to predict (with variable accuracy) the defining properties of stem cells, which are probed in vivo, markers can in turn only be identified through the use of in vivo assays.
Generation of a heterotopic ossicle is the assay that defines bone marrow-derived MSCs, as teratoma formation defines pluripotent cells and hematopoietic reconstitution defines HSCs. Heterotopic transplantation aims to show the inherent ability of a given cell strain to generate histology-proven skeletal tissues independent of exogenous, skeletogenic cues that would either be applied ex vivo or come in vivo from grafting cells within a bone (orthotopic transplantation). The identification of multipotent, self-renewing bone marrowderived MSCs was specifically established by a sequential series of in vivo experiments refined stepwise over several decades (see illustration).
1. Transplantation of boneless, whole bone marrow fragments results in the formation of heterotopic ossicles (miniature bone organs that include the hematopoietic microenvironment), revealing the existence of a skeletogenic potential within bone marrow and representing the seminal experiment that paves the way to identifying MSCs 5 . 2. Generation of heterotopic ossicles by transplantation of stromal (adherent, nonhematopoietic) cell strains in lieu of tissue fragments ascribes the skeletogenic potential to the nonhematopoietic fraction of bone marrow. In these experiments, conducted before the development of cell sorting, cell culture is, in essence, used to separate stromal from hematopoietic cells. 3. Generation of heterotopic ossicles by transplantation of cell strains from multiple CFU-Fs establishes the existence of in vivoassayable stromal progenitors in the bone marrow. Here, clonogenicity in vitro is used to define the stromal progenitors, which are, by analogy with clonogenic hematopoietic progenitors, able to generate colonies of hematopoietic cells in methyl cellulose (colony-forming cell assays) 6 . 4. Generation of heterotopic ossicles from single clones, grown from a single progenitor (CFU-F), proves that the individual clonogenic progenitor is a multipotent progenitor of skeletal tissues. All tissues in the ossicle (bone, adipocytes and fibroblasts) are derived from a single clonogenic progenitor through its clonal progeny, which are generated in vitro and then transplanted in vivo 56 . 5. Formation of heterotopic ossicles by single progenitors explanted from the bone marrow on the basis of a defined phenotype followed by secondary passage and transplantation of identical cells harvested from the ossicle establishes that multipotent progenitors can also self renew 2, 3 . combined immunodeficiency (ADA-SCID) 21 and epidermolysis bullosa (EB) 22 . Likewise, the notion of a stem cell that can be handled or modified ex vivo and transplanted in vivo would encourage attempts to tackle crippling or lethal diseases that affect the skeleton systemically, such as osteogenesis imperfecta or fibrous dysplasia.
Here, insufficient consideration of the inherent specific biology of skeletal and connective tissues (their three-dimensional nature, slow turnover, matrix-centered cell cueing and vascularity) and their radical diversity in many functional and structural respects from blood or epithelia has often resulted in hasty attempts toward translation. For example, early attempts to correct osteogenesis imperfecta by bone marrow transplantation [23] [24] [25] made naive, untested assumptions regarding the biological properties of MSCs. (An ability to efficiently engraft through the circulation reflects, for hematopoietic stem cells, unique developmental and physiological processes 26 ; different processes and paths, however, underpin the development, growth and systemic distribution of bone cells 27 .) Simple or complex, immediate prospects or wishful thinking, all these approaches are logically linked to the biological concept behind them and the evidence behind the concept; as we learn that a stem cell for skeletal tissues exists, we next try to harness its proven physiological function. This simple conceptual framework (organ-specific stem cells for organ-specific diseases), not surprisingly, is the one in which all instances of clinically successful translation of stem-cell science in medicine, one of which has had an epochal impact, are inscribed: bone marrow transplantation 28 , regeneration of skin [29] [30] [31] and regeneration of cornea 32, 33 .
The clash of two concepts
The fundamental science to be harnessed in this conceptual framework is precisely sculpted: it portrays committed multipotent progenitors for skeletal tissues and skeletal tissues only and defines them as residing within the bone marrow and not elsewhere or everywhere and as locally transplantable but not necessarily systemically transplantable. This precise notion, and all the prior science behind it, was imprecisely used in the 1990s to formulate a quite different concept 7 . This different concept was to become popular and irreversibly linked to the term 'mesenchymal stem cell' , which has now attained universal use. The 'revisionist' concept departs from the original notion in two important respects. First, it postulates a common progenitor not just of skeletal tissues but of all nonepithelial, nonhematopoietic tissues derived from the mesoderm, including skeletal muscle, myocardium, endothelium and others that are seen as part of a hypothetical 'mesengenic process' 34 . Second, it assumes that such progenitors are found in not only the bone marrow but also a number of other tissues and virtually all postnatal organs 35 . Neither point has been proven: the hypothetical mesengenic process has remained unverified and difficult to precisely reconcile with some established facts in developmental biology. Experimentally, whereas the original concept of skeletal stem cells was (and remains) rooted in stringent in vivo transplantation and single-cell assays, the revisionist concept is complemented by nonstringent in vitro assays and does not make use of single-cell analysis.
An awkward position
Crystallized in a widely cited position paper that assumed to set the criteria for defining MSCs for general use 36 Figure 1 The whereabouts of MSCs. In the postnatal bone marrow, MSCs reside around sinusoids, maintain a niche for HSCs, support hematopoiesis and replenish the differentiated compartment of osteoblasts and adipocytes during tissue growth and turnover; they also generate cartilage under specific conditions such as trauma. Total populations of bone marrow stromal cells (BMSCs), which do not coincide with cultures of stem cells in any way, are established when total bone marrow cell suspensions are plated in culture at high density. Adherence to plastic separates the stromal cells from nonadherent hematopoietic cells. If cell suspensions are plated at low density, only cells capable of density-insensitive growth are selected. These cells initiate the growth of clonal colonies. Passaging a single colony or, alternatively, establishing a clonal culture from single cells isolated on the basis of their expression of phenotypic markers, which may be different in human and mouse, results in a clonal population that can be used to assess multipotency by in vivo transplantation. Heterotopic ossicles include multiple differentiated cell types of donor origin (osteoblasts, (Box 2) , the artificial properties seen as 'defining' features of MSCs are simply widely shared properties of connective tissue cells. They do not imply any true stem-cell property or the true ability to form bone, cartilage or adipose tissue in vivo. The confusion introduced by these criteria has major consequences when translational implications are considered. If they are predicted based on unreliable in vitro criteria, all the properties of the MSC to be harnessed in patients (such as the ability to regenerate bone, in the simplest scenario) are predicted unreliably: placenta, menstrual endometrium and bone become conceivably equivalent sources of cells for efficient bone regeneration, but they absolutely are not. Additionally, one could conceive a clinical trial to treat Duchenne's muscular dystrophy (a lethal disease) with fat-derived MSCs, which are claimed to be more efficiently myogenic than genuine myoblasts 37 . More generally, as the range of clinical conditions considered potentially treatable by systemically administered MSCs expands and relevant clinical trials are initiated, it is the mere intravenous infusion of nondescript cultured connective tissue cells in patients that becomes confused with, but proposed and presented as, a stem cell-based therapy.
Wrapped around your vessel
The demonstration that in human bone marrow, MSCs are perivascular cells 2 (an observation later reproduced in the mouse 3 ) led some to contend that pericytes and MSCs are coinciding entities. Combined with the speculation that MSCs are ubiquitous, this idea would conveniently identify pericytes as the ubiquitous in situ counterpart of the ubiquitous MSCs 37, 38 . Pericytes are perivascular cells found in all tissues, are not a distinct lineage and are recruited to blood-vessel walls from the surrounding tissue during organ development and growth [39] [40] [41] . The idea that distinct classes of lineage-restricted, tissue-specific Box 2 What can be determined from a culture of bone marrow stromal cells
Cultures of bone marrow stromal cell populations (improperly referred to as cultures of MSCs) can be established through two different procedures. The conventional method involves the direct establishment of cultures from total bone marrow cell suspensions and is based on isolation by plastic adherence (Fig. 1) . If cell suspensions are plated in bulk (nonclonal density), monolayers of nonhematopoietic, adherent cells are generated, representing cultures of total bone marrow stroma and not stem cells. Both stromal progenitors (clonogenic cells and CFU-Fs) and stromal cells that are neither stem cells nor progenitors but are capable of limited growth contribute to these cultures. These cultures cannot be used for assays of multipotency. By plating the cell suspension at clonal density, multiple stromal colonies are generated, where each colony is the clonal progeny of a single stromal progenitor or stem cell (CFU-F). When all colonies are passaged together and further cultured, the resulting cell strain is the progeny of multiple clonogenic stromal progenitors, which typically differ from one another in differentiation potential. These cultures, again, cannot be used to assess multipotency. When a single colony is harvested and cultured, the resulting cell strain is the clonal progeny of a single stromal progenitor. These cultures can therefore be used to assess multipotency. Pending the development of methods for transplanting a single, uncultured progenitor, which must necessarily be identified by phenotype, in vivo transplantation of the clonal progeny of a single clonogenic progenitor is the standard assay for probing (proving) multipotency. Growing clones of mouse MSCs in vitro is more problematic than growing clones of human MSCs, and it imposes specific technical hurdles that may be circumvented in different ways 3, 64 .
An alternative method of isolation is based on surface phenotype: so-called 'prospective' isolation ( Fig. 1) . This necessarily involves the use of one or more markers (STRO-1, CD146, CD105, ALP, CD49a and CD271, among others, in humans and nestin, CD105, VCAM1, CD90 and others in mice) for cell sorting. Plating the sorted population at clonal density results in the establishment of progenitor (CFU-F)-initiated colonies; the frequency and relative representation of CFU-Fs (stromal progenitors) within the phenotypedefined population are estimated by colony-forming efficiency assays. A purified population of progenitors would have a colonyforming efficiency of 100% at clonal density (<1.6 cells per cm 2 ). A purified population of stem cells would be comprised of cells that are uniformly multipotent and uniformly self renewing, as assessed by in vivo transplantation. progenitors would in the same way and through the same mechanisms (the platelet-derived growth factor BB (PDGF-BB)-PDGF receptor β (PDGFRβ) loop, angiopoietin 1 (Ang-1) and transforming growth factor β1 (TGF-β1)) be recruited to, and stabilized within, microvessel walls from the local environment in developing and growing tissues was recently proposed 2 . This idea would explain why skeletal progenitors are perivascular in the bone marrow, some perivascular cells in skeletal muscle are myogenic 42 and adipocyte progenitors in adipose tissue are perivascular 43 . Far from being consistent with the opposite idea that the ubiquitous pericytes coincide with the ubiquitous multilineage MSCs 37, 44 , these data suggest that specific classes of tissue progenitors with specific differentiation capacities can be isolated from different tissues 4 . The perivascular position of these cells in different tissues, reflected in the shared expression of adhesion molecules mediating the interaction with endothelial cells through homophilic interaction (melanoma cell adhesion molecule (MCAM or CD146)) and surface receptors or antigens involved in the regulation of perivascular cells (for example, PDGFR-β (CD140b) or CD105 (endoglin)), could provide a lead to efficient prospective isolation. To prove this, identical conditions for cell isolation, culture and in vivo transplantation in rigorous assays must be defined and used. These studies could provide major advances regarding how to identify and isolate specific classes of tissue progenitors for specific regenerative applications in specific tissues and organs.
Plasticity melts
During the past decade, a number of studies have pursued the idea that a broad range of extraskeletal tissues could be directly regenerated by MSCs. Notably, these tissues included not only extraskeletal tissues that are otherwise derived from the mesoderm (as are skeletal tissues, except the facial bones) but also derivatives of other germ layers, such as liver cells or neurons 45 . Inscribed in a broader trend claiming the transgermal plasticity of somatic postnatal stem cells, the idea was entertained or implied for the last decade that MSCs or subsets thereof could be pluripotent cells, similar to embryonic stem cells 46 . A number of in vitro studies claimed efficient differentiation of chemically cued MSCs into disparate nonskeletal cell types as a prelude to more daring preclinical and clinical studies. Less than rigorous criteria for assessing differentiation in artificial in vitro systems and more than empirical ways of altering a cultured cell phenotype (a serendipitous, empirical, partial reprogramming ante litteram) were a unifying thread of virtually all of these studies. In retrospect, it seems reasonable to trace the intensive efforts toward achieving unorthodox, chemically directed differentiation of postnatal stem cells to the intellectual impact of the directed differentiation of pluripotent embryonic cells.
However, all the best-known and clinically harnessed types of postnatal stem cells are system specific. Their system-specific potential is cell autonomous and not cued. In vitro cueing is well suited to explore technologies for directing the differentiation of pluripotent embryonic stem cells. However, this does not necessarily represent a paradigm that can be generalized to all entities sharing the name 'stem cells' . In retrospect, exogenous cueing of the directed differentiation of postnatal 'mesenchymal' stem cells is perhaps best seen as reprogramming (change of potential) rather than differentiation (expression of potential). For example, C2C12 myoblasts or endothelial cells can be reprogrammed to an osteogenic phenotype by BMP-2-SMAD signaling 47, 48 , which induces the master transcription factors regulating osteogenesis, Runx2 and Osx (SP7), the latter of which was indeed discovered in BMP-treated C2C12 cells 49 . Yet noncued C2C12 cells or endothelial cells do not spontaneously form bone if transplanted in vivo, which is what skeletal progenitors do. Likewise, induction of liver cell-like phenotypic traits in bone marrow stromal cells 46, 50 does not mean either an inherent nature of stromal cells as liver-cell progenitors or that true liver cells can be obtained in this fashion with the efficiency and robustness that any conceivable translational purpose would imply. Enthusiasm and applicative motivations (hypes and hopes) prevailed at times over caution and rigor, with some unfortunate pitfalls. In this way, for example, the reversible effects of agonists of adenylyl cyclase on F-actin and cell shape, long and widely known 51 , were freely interpreted in several studies as the induction of a neuron-like phenotype in bone cells 45 , whereas in reality they merely represented transient cytoskeletal disruption.
Can do, can't do
The idea that MSCs are pluripotent is now on the wane. Just as the echo of the isolation in culture of human embryonic pluripotent stem cells cast on the minds of many the suggestion that all cells called stem cells could be pluripotent, the echo of evidence that somatic cells (including MSCs 52 ) need, in fact, to be reprogrammed through defined protocols of transduction with defined sets of transcription factors 53 to become pluripotent has now put the idea to rest. Nonetheless, a number of preclinical and clinical studies were planned and conducted over the last ten years aiming at regenerating the infarcted heart or brain using cells whose ability to regenerate myocardium or brain was simply never proven. Almost invariably, these studies recorded some kind of effect that was defined as beneficial; actual differentiation into relevant cell types in vivo was claimed in early studies but not confirmed in later ones. The notion that MSCs could regenerate the infarcted heart or the brain has not met experimental proof, yet the notion that MSCs can nonetheless be beneficial for the infarcted heart or brain is still entertained. A number of clinical trials worldwide are currently pursuing evidence of such effects. At this time, a widely shared line of thinking contends that MSCs, although not endowed with properties of pluripotent cells and thus unable to regenerate target, nonskeletal tissues, still can exert beneficial effects of clinical relevance on a number of extraskeletal organs through mechanisms unrelated to a progenitor function 54, 55 .
As a progenitor or not as a progenitor
The idea that MSCs can exert functions other than those characteristic of a stem or progenitor cell (tissue regeneration) is conceptually intriguing and certainly supported by direct evidence. One defining feature of bone marrow-derived MSCs is to establish, organize and transfer the hematopoietic microenvironment or niche in vivo 2, 16, 56 . In in vivo systems that can recapitulate the ontogeny of bone and marrow, this function is intertwined with the organization of nascent blood vessels into functional networks, which seems to be directed by MSCs through direct interaction with endothelial cells 2 . In other experimental systems that were not designed or suited to allow for the skeletogenic potential of MSCs to unfold, their ability to organize vascular networks can be portrayed even in isolation, meaning in the absence of bone or bone marrow [57] [58] [59] . Thus, at least with respect to hematopoietic cells (including hematopoietic stem cells) and endothelial cells, MSCs exert a function that is not immediately traceable to a general stem-cell property. Indeed, the ability of transplanted MSCs to act at the same time as progenitors of skeletal tissues of donor origin and as an organizer of recipient tissues is unique among all cells that are called stem cells. However, these nonprogenitor functions of MSCs are so far restricted to bone marrow-derived MSCs and only npg p e r s p e c t i v e documented when MSCs are locally, not systemically, transplanted and engrafted. Of note, although only partially understood, the mechanisms behind these properties of MSCs are not shrouded in obscurity or vagueness: their interaction with endothelial and hematopoietic cells is mediated by known factors such as fibroblast growth factor 2 (FGF-2), PDGF-BB, TGF-β1, Ang-1 and CXCL-12 and their specific role as either producers of or responders to such factors 2, 39 . Such a role for bone marrow-derived MSCs in these functions is coherent with the established functions of these factors themselves in vascular and hematopoietic cell biology. Although still not at hand, a general picture of how bone marrow-derived MSCs can regulate important physiological functions such as hematopoiesis, hematopoietic stemcell physiology and the assembly and remodeling of vascular lattices can be reasonably expected to be completed in a foreseeable future. Indeed, recognizing the role of MSCs in these processes and dissecting that role further highlights innovative avenues for translation. These functions, at variance with others, are reasonably defined, can be reproducibly modeled in vivo and can thus be dissected to the measure required to envision a clinical use, albeit not immediately. For example, the role of MSCs, specifically, bone marrow-derived MSCs, as potential key contributors to the niche effect that characterizes HSC biology has clear implications for devising strategies for the expansion of HSCs, a remaining major hurdle in clinical hematology 60 . Likewise, learning how to harness the vessel-remodeling functions of MSCs might improve tissue vascularity in different scenarios.
Lost in translation
In sharp contrast, other functions of MSCs that are evoked as a reason to move fast from insufficient science to translation or therapy are not clearly defined. Variably referred to as trophic, antiinflammatory or immune modulatory, these effects, seen from a distance, do evoke at least the flavor of the type of regulatory function that MSCs exert in their physical existence as bone marrow stromal cells. With some measure of imagination, one could relate the regulation of immune and inflammatory cells to at least the regulation of cells of hematopoietic lineage. However, some of the nonprogenitor effects of MSCs, such as immune modulation predicted by inhibition of the mixed lymphocyte reaction, are not the effects of stem cells, as they are duplicated by cultures of fibroblasts 61 . Furthermore, the precise identity of such regulatory functions (and as an unavoidable consequence, their mechanisms) remains unknown and unverified at best. Both the effects and mechanisms have escaped conclusive validation in defined in vivo model systems thus far. All regulatory functions of MSCs (of any cell) are expected to be tightly regulated and occur in defined contexts of tissue physiology; understanding this regulation and these contexts would be crucial for their harnessing. Inflammation and its abatement, for example, occur sequentially in tissues and involve substantial, sequential modulation of functions of individual cell types. Wound healing and tissue regeneration, likewise, do not coincide with one another: a scar heals a wound but is not a regenerated organ. Presumed roles of MSCs in each type of process are often confused with one another. When inscribed in a translational perspective, necessary distinctions are further blurred: paracrine effects are said to operate in injured organs regardless of the nature of the injury, which, of course, results in the generation of very different local milieus, microenvironments and patterns of cell response. Whether inflammatory (Crohn's disease), infectious (sepsis), ischemic (myocardial infarction or stroke), metabolic (blood glucose control) or degenerative (Parkinson's disease) in nature, it would seem that all diseases (injuries) of all organs would benefit from MSCs 55 .
The notion of specific remedies for specific disease mechanisms is at the heart of both successful and contemporary medicine. Historically, it is perhaps this single idea that most sharply demarcates the emergence of modern medicine from the alchemic tradition (which pursued a single cure for all ailments-the 'panacea') and the empiricism that formed the entire substance of medicine for approximately 40 centuries. It is in not only the lack of a proven mechanism but often the lack of a plausible hypothetical mechanism that MSCs are intravenously infused into patients with heart attacks, renal failure, stroke, diabetes, Crohn's disease or Parkinson's disease; they are envisioned or proposed as a treatment for autism, Huntington's disease and dozens of other unrelated conditions that seem unlikely to represent reasonable targets. This creates expectations in patients and their families that are not likely to be met. Conversely, tipping the balance of experimentation in favor of clinical trials rather than reproducible experiments also has an impact: it leaves in the shadow the need to define and tackle specific mechanisms and pursue solid, conclusive evidence. The extent to which the purported paracrine beneficial effects of MSCs in all the targeted conditions truly represent an indispensable role of cells (which could, for example, regulate other cells through cell-cell contacts but require engraftment to do so) rather than the role of one or more released factors cannot be addressed in the absence of defined and reproducible models. In addition, dispensable or indispensable as a role of cells may be, it would remain unclear whether that role is one of stem cells, of cells, of cultured cells or of cultured cells injected and impacted in blood vessels.
Furthermore, this question cannot, by definition, be addressed by clinical trials, particularly when conducted in the absence of a reasonable understanding of pharmacokinetics of the administered 'drug' (cells) and a solid rationale. Intravenously injected MSCs embolize in the lungs, where they cause endothelial damage 62, 63 , which is a nonnegligible, general adverse effect; they are then cleared in a matter of hours. Therefore, whatever paracrine effect they exert, on whatever pathological process, must be short lived and may be related to cell death. Clearly, intravenous infusion of cells that do not engraft cannot be defined as transplantation. Effects of infused cells that are neither transplanted nor engrafted and do not regenerate tissues do not reflect a stem-cell or regenerative function, and their pursuit should not be presented as a stem cell-based or regenerative therapy. The issue is not trivial and not intended to discount the role of empiricism in the discovery of medicines. In the history of medicine, with all kinds of medicines (cell products) ultimately being identified in either the vegetable or animal kingdom (digitalis or steroids and morphine or insulin, to name the simplest), recognition of an empirically identified biological effect led to the isolation, or synthesis, and use of the active principle and an understanding of its mode of action. If indeed MSCs were affecting tissue injury and repair through paracrine factors as is commonly claimed, then the factors, not the cells, would be the medicine. Then, intravenous injections of cells in patients, as opposed to the pursuit of the factors and their mechanisms at the bench, would turn into the opposite of a true translational approach. It is only sense, what one can translate.
Looking ahead
It is odd that at precisely the time when MSCs evolve from an experimentally derived hypothesis into a recognizable entity, translational approaches centered on MSCs seem to drift away from the hypothesis, the recognizable entity and the general paradigm that links stemcell properties to regenerative medicine (Fig. 3) . Verified by current data, the potential of the original concept, which first highlighted npg the functional continuity encrypted in a single cell of a single system made of bone and bone marrow, effectively fertilizes both basic science and translational opportunities in multiple, and at times new, directions. The roles of MSCs as niche cells, tissue organizers and direct skeletal progenitors open opportunities and pose challenges. Grasping the unique nature of the system and specific stem cell is necessary to identify how to harness science for therapy, which may involve entirely new methods and a broad range of intermediate steps. These go far beyond the empirical injection of poorly characterized cultured cell strains. Multiple avenues are open and include (i) stem cell-based modeling of disease mechanisms, (ii) identification of cell-derived bioactive factors and their use as drugs, (iii) definition of drug-targetable disease mechanisms operating specifically in the stem cells or the broad system of interrelated tissues they rule, and (iv) identification of strategies for cell delivery that take into account the specificities of the system and permit the design of gene therapy strategies; all these are largely unexplored. Case histories of success in regenerative medicine reveal century-long scientific backgrounds. MSCs are truly the newcomers to the club or are perhaps the founders of a new one. Give them time and serious effort.
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